Mappings Pathways

2013 • 129 sayfa • EN

Yazan Molly Morgan Jones, Jim Pickett, Joanna Chataway, James Swartz, Ohid Yaqub, Philip Smith, Kartika Palar, Jessica Terlikowski, Daniella Mark, William McColl, Petal Jean Hackett, Catriona Manville, Peter Glick, RAND Europe, Rand Corporation, Merck & Co

Mapping Pathways is a multinational project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral (ARV)-based prevention strategies to end the HIV/AIDS epidemic. The project is based on the premise that the current array of prevention options is not sufficient; new pathways to prevention, based on enhanced assessment and analysis of likely impact, are needed to address new infections adequately. ARVs are opening up new options for HIV prevention, such as 0́8treatment as prevention0́9 (often referred to as 0́8TLC+0́9 [testing, linkage to care], plus treatment), microbicides, oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). There are multifaceted challenges associated with these new prevention strategies related to access, cost, behavioural and health impacts, and implementation. Mapping Pathways 0́3 Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention is designed to support critical thinking and development of a new research agenda for the analysis of multiple policy options 0́3 the pathways 0́3 that should be considered by prevention planners, programmers and funders when addressing the opportunities and challenges of the new ARV paradigm.